

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on December 27, 2011.

PATENT

Attorney Docket No.: 87331-008100US-712937

Client Reference No.: E1-A0307P-US

KILPATRICK TOWNSEND & STOCKTON LLP

By: 

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Yuichi ONO et al.

Application No.: 10/580,989

Filed: March 29, 2007

For: SPECIFIC MARKER LMX1A ON  
DOPAMINERGIC NEURONS

Customer No.: 20350

Confirmation No.: 5847

Examiner: KOLKER, Daniel E.

Art Unit: 1649

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Commissioner:

The references cited on attached form PTO/SB/08A&B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This Information Disclosure Statement is being filed with an RCE. Applicant believes that no fee is required for submission of this statement.

Respectfully submitted,



Kevin Bastian  
Reg. No. 34,774

KILPATRICK TOWNSEND & STOCKTON LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:ack